| Overview |
| bsm-60736R-Cy5.5 |
| PD1 (6H11) Monoclonal Antibody, Cy5.5 Conjugated |
| IF(ICC) |
| Human |
| Specifications |
| Cy5.5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human PD1 |
| Monoclonal |
| 6H11 |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 5133 |
| Q15116 |
| Programmed cell death protein 1; CD279; CD279 antigen; hPD 1; hPD-1; hSLE1; PD 1; PD1; PDCD 1; PDCD1; PDCD1_HUMAN; Programmed cell death 1; Protein PD 1; Protein PD-1; SLEB2; Systemic lupus erythematosus susceptibility 2. |
Programmed cell death protein 1 (PDCD1) is an immune-inhibitory receptor expressed in activated T cells; it is involved in the regulation of T-cell functions, including those of effector CD8+ T cells. In addition, this protein can also promote the differentiation of CD4+ T cells into T regulatory cells. PDCD1 is expressed in many types of tumors including melanomas, and has demonstrated to play a role in anti-tumor immunity. Moreover, this protein has been shown to be involved in safeguarding against autoimmunity, however, it can also contribute to the inhibition of effective anti-tumor and anti-microbial immunity. [provided by RefSeq, Aug 2020]
|
| Application Dilution |
| IF(ICC) |
1:50-200 |
Powered by Bioz